Abstract
Twenty-five to thirty percent of patients with node-negative breast cancer are expected to relapse following surgery, therefore great efforts have been made to identify new prognostic markers that could be useful in defining patients for additional therapy. The expression of MMP-2 and MMP-9 has been associated with high potential of metastasis in several human carcinomas including breast cancer. In the present study we examined the prognostic value of immunoreactive MMP-2/MMP-9 protein in 270 consecutive lymph node negative cases who received radical mastectomy or modified radical mastectomy. Among the patients, 211 cases received adjuvant endocrine therapy and/or adjuvant chemotherapy. Using immunohistochemical assay, we found that 56.7% of the resected tumors were positive for MMP-2 whereas 59.6% of the samples were positive for MMP-9. χ2 test demonstrated a significant direct association between MMP-2 and MMP-9 ( p < 0.001); positive immunostaining of MMP-2 was significantly related to higher tumor grade ( p < 0.001) and larger tumor size ( p=0.012); positive immunostaining of MMP-9 was significantly related to higher tumor grade ( p=0.002). In univariate analysis, using Cox-proportional hazard model we found MMP-2, MMP-9 and the co-expression of MMPs (MMP2/MMP9) were significantly associated with patients' relapse free survival ( p=0.016, 0.015 and 0.013 respectively) but not overall survival ( p=0.122, 0.320 and 0.091 respectively). Log-rank test also showed that MMP-2, MMP-9 or the co-expression of MMP2/MMP9 was unfavorable prognostic factor for relapse free survival but not overall survival. In subgroup analysis, we found MMPs were more prognostic for patients with no adjuvant treatment than for patients with adjuvant therapy. In multivariate analysis, using Cox-proportional hazard model we found co-expression of MMPs, larger tumor size and higher tumor grade were unfavorable for relapse free survival ( p=0.038, 0.007 and 0.015 for each). We concluded that MMP-2 and MMP-2 are unfavorable prognostic factors in breast cancer patients. They might be potential predictive factor for adjuvant systemic therapy. The co-expression of MMP-2 and MMP-9 has significantly prognostic value in node-negative patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Chambers AF, Matrisian LM: Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 89: 1260–1270, 1997
Liotta LA, Wewer U, Rao NC, Schiffmann E, Stracke M, Guirguis R, Thorgeirsson U, Muschel R, Sobel M: Biochemical mechanisms of tumor invasion and metastases. Prog Clin Biol Res 256: 3–16, 1988
Liotta LA, Stetler-Stevenson WG: Metalloproteinases and cancer invasion. Semin Cancer Biol 1: 99–106, 1990
Duffy MJ: The biochemistry of metastasis. Adv Clin Chem 32: 136–166, 1996
Duffy MJ: Do proteases play a role in cancer invasion and metastasis? Eur J Cancer Clin Oncol 23: 583–589, 1987
Talvensaari-Mattila A, Paakko P, Hoyhtya M, Blanco-Sequeiros G, Turpeenniemi-Hujanen T: Matrix metalloproteinase-2 immunoreactive protein: a marker of aggressiveness in breast carcinoma. Cancer 83: 1153–1162, 1998
Talvensaari-Mattila A, Paakko P, Turpeenniemi-Hujanen T: MMP-2 positivity and age less than 40 years increases the risk for recurrences in premenopausal patients with node-positive breast carcinoma. Breast Cancer Res Treat 58: 287–293, 1999
Hirvonen R, Talvensaari-Mattila A, Paakko P, Turpeenniemi-Hujanen T: Matrix metalloproteinase-2 (MMP-2) in T1–2N0 breast carcinoma. Breast Cancer Res Treat 77: 85–91, 2003
Scorilas A, Karameris A, Arnogiannaki N, Ardavanis A, Bassilopoulos P, Trangas T, Talieri M: Overexpression of matrix-metalloproteinase-9 in human breast cancer: a potential favorable indicator in node-negative patients. Br J Cancer 84: 1488–1496, 2001
Daidone MG, Silvestrini R, D'Errico A, Di Fronzo G, Benini E, Mancini AM, Garbisa S, Liotta LA, Grigioni WF: Laminin receptors, collagenase IV and prognosis in node-negative breast cancers. Int J Cancer 48: 529–532, 1991
Pacheco MM, Mourao M, Mantovani EB, Nishimoto IN, Brentani MM: Expression of gelatinases A and B, stromelysin-3 and matrilysin genes in breast carcinomas: clinicopathological correlations. Clin Exp Metastasis 16: 577–585, 1998
Remacle AG, Noel A, Duggan C, McDermott E, O'Higgins N, Foidart JM, Duffy MJ: Assay of matrix metalloproteinases types 1, 2, 3 and 9 in breast cancer. Br J Cancer 77: 926–931, 1998
Elston CW, Ellis IO: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19: 403–410, 1991
Talvensaari-Mattila A, Paakko P, Blanco-Sequeiros G, Turpeenniemi-Hujanen T: Matrix metalloproteinase-2 (MMP-2) is associated with the risk for a relapse in postmenopausal patients with node-positive breast carcinoma treated with antiestrogen adjuvant therapy. Breast Cancer Res Treat 65: 55–61, 2001
Kute TE, Shao ZM, Sugg NK, Long RT, Russell GB, Case LD: Cathepsin D as a prognostic indicator for nodenegative breast cancer patients using both immunoassays and enzymatic assays. Cancer Res 52: 5198–5203, 1992
Saez RA, McGuire WL, Clark GM: Prognostic factors in breast cancer. Semin Surg Onco 15: 102–110, 1989
Robertson J: Prognostic and response markers in the management of breast cancer. Cancer treatment Rev 23: S41–S48, 1997
Rha SY, Yang WI, Kim JH, Roh JK, Min JS, Lee KS, Kim BS, Chung HC: Different expression patterns of MMP-2 and MMP-9 in breast cancer. Oncol Rep 5: 875–879, 1998
Talvensaari-Mattila A, Paakko P, Hoyhtya M, Blanco-Sequeiros G, Turpeenniemi-Hujanen T: Matrix metalloproteinase-2 immunoreactive protein: a marker of aggressiveness in breast carcinoma. Cancer 93: 1153–1162, 1998
Baker EA, Stephenson TJ, Reed MW, Brown NJ: Expression of proteinases and inhibitors in human breast cancer progression and survival. Mol Pathol 55: 300–304, 2002
Wang TN, Albo D, Tuszynski GP: Fibroblasts promote breast cancer cell invasion by upregulating tumor matrix metalloproteinase-9 production. Surgery 132: 220–225, 2002
Kondo S, Kubota S, Shimo T, Nishida T, Yosimichi G, Eguchi T, Sugahara T, Takigawa M: Connective tissue growth factor increased by hypoxia may initiate angiogenesis in collaboration with matrix metalloproteinases. Carcinogenesis 23: 769–776, 2002
Pacheco MM, Nishimoto IN, Mourao Neto M, Mantovani EB, Brentani MM: Prognostic significance of the combined expression of matrix metalloproteinase-9, urokinase type plasminogen activator and its receptor in breast cancer as measured by Northern blot analysis. Int J Biol Markers 16: 62–68, 2001
Curran S, Murray GI: Matrix metalloproteinases in tumor invasion and metastasis. J Pathol 189: 300–308, 1999
Baker EA, Bergin FG, Leaper DJ: Matrix metalloproteinases, their tissue inhibitors and colorectal cancer staging. Br J Surg 87: 1215–1221, 2000
Franchi A, Santucci M, Masini E, et al.: Expression of matrix metalloproteinase 1, matrix metalloproteinase 2, and matrix metalloproteinase 9 in carcinoma of the head and neck. Cancer 95: 1902–1910, 2002
Duffy MJ, McCarthy K: Matrix metalloproteinases in cancer: prognostic markers and targets for therapy. Int J Oncol 12: 1343–1348, 1998
Duffy MJ, Maguire TM, Hill A, McDermott E, O'Higgins N: Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res 2: 252–257, 2000
Hiraoka N, Allen E, Apel IJ, et al.: Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins. Cell 95: 365–377, 1998
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Li, Hc., Cao, Dc., Liu, Y. et al. Prognostic value of matrix metalloproteinases (MMP-2 and MMP-9) in patients with lymph node-negative breast carcinoma. Breast Cancer Res Treat 88, 75–85 (2004). https://doi.org/10.1007/s10549-004-1200-8
Issue Date:
DOI: https://doi.org/10.1007/s10549-004-1200-8